ProShares MSCI Transformational Changes ETF (ANEW)
ARCA ARCA Primary 
XBER 
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity New York, NY, September 17, 2024 – PRISM MediaWire – The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com.
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 – PRISM MediaWire – ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development.
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors.
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
New York, NY. August 21, 2024 – ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Appoints New CFO
New York, NY, August 19, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.
ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases
Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW's IP for development and commercialization in the U.S. New York, NY, August 15, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
NEW YORK, NY, August 09, 2024 – ANEW MEDICAL, INC.
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and Canada NEW YORK, July 9, 2024 — ANEW MEDICAL, INC.
ANEW MEDICAL Forms Strategic Partnership with Japan's Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
Collaboration focuses on research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW's mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June, 27. 2024 — ANEW MEDICAL, INC.
